RxDoctor Payments Data

Jacqulynn Poe

Nurse Practitioner · Springfield, MONPI 1578911350

Payments from drug & device makers

$3,952in general payments, 2019–2025

Across 186 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$685
  • Amgen$475
  • Johnson & Johnson$416
  • Kestra Medical Technology Services, Inc.$395
  • E.r. Squibb & Sons, L.L.C.$213
  • Boehringer Ingelheim$204
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,93199%
  • Gifts$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,952 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$8,296
Medicare patients
102
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor104$53,805
EliquisApixaban38$26,169
Ranolazine ErRanolazine14$1,613
Metoprolol Succinate122$568
ClopidogrelClopidogrel Bisulfate101$469
Atorvastatin Calcium118$469
Ezetimibe24$313
Isosorbide Mononitrate ErIsosorbide Mononitrate73$193
Rosuvastatin Calcium43$182
Pantoprazole Sodium32$148
Carvedilol63$139
Spironolactone35$120
Lisinopril47$119
Famotidine19$103
Losartan Potassium37$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$135$53,805104 claims
PfizerEliquis$57$26,16938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →